Developing anti-CD19 antibody-based combinations in lymphoma

Affiliations

Comment

John Kuruvilla. Lancet Oncol. 2020 Jul.

. 2020 Jul;21(7):870-872.

doi: 10.1016/S1470-2045(20)30275-8. Epub 2020 Jun 5.

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. Electronic address: john.kuruvilla@uhn.ca.

No abstract available

Comment on

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Salles G, et al. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. Lancet Oncol. 2020. PMID: 32511983 Clinical Trial.